Crispr Therapeutics Stock Been: A Roller-Coaster Year Unpacked
CRISPR Therapeutics stock has zigzagged all year, driven by pipeline milestones, regulatory updates, and funding need...
This intro points out equity indices that qualify as total return and explains how dividends affect performance reporting.
24,588 articlesCRISPR Therapeutics stock has zigzagged all year, driven by pipeline milestones, regulatory updates, and funding need...
A fast-tracked Nasdaq-100 adds a new catalyst for space stocks. Rocket Lab is poised to enter the index ahead of Spac...
Bitcoin sits near the $65,000 mark as global headlines churn. This morning minute breaks down the drivers behind the ...
Uber trades lower after peaking earlier in the year, but quarterly earnings rose sharply as the company leans into au...
CoStar Group stockholders reaffirm board support at Tuesday's annual meeting, backing eight directors and an updated ...
A prominent contrarian investor has revealed a bold, long-term bet on Microsoft, using December 2028 LEAP calls to ca...
Markets confront a paradox: AI’s potential is immense, but real-world adoption is uneven. Household budgets and inves...
A leading venture figure signals a six-day, in-office funding filter, prompting founders to rethink work arrangements...
Gen Z accounted for a record 20% of rate locks in Q2, marking a major shift in the homebuying landscape as affordabil...
Oil futures climbed after the U.S. Treasury canceled a license that allowed limited Iranian oil sales, triggering a f...
Global AI investment is accelerating as firms move from pilots to wide-scale deployment. The ai’s trillion opportunit...
Three tech giants moved in sync for the first time in years, powered by AI momentum. Here’s how to interpret the sign...